Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 7:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 757 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Glaucoma
Interventions
Not listed
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated May 27, 2012 · Synced May 21, 2026, 7:13 PM EDT
Conditions
Glaucoma, Ocular Hypertension
Interventions
latanoprost 0.005% ophthalmic solution, Travoprost 004% sterile ophthalmic solution, Bimatoprost .03% sterile ophthalmic solution
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
40
States / cities
Bellflower, California • Inglewood, California • San Diego, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced May 21, 2026, 7:13 PM EDT
Conditions
Glaucoma, Open-Angle
Interventions
Standard Automatic Perimetry Humphrey Field Analyzer, visuALL H, iCare Home Tonometer, Spectralis Optical coherence tomography (OCT)
Diagnostic Test
Lead sponsor
Wills Eye
Other
Eligibility
20 Years to 80 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced May 21, 2026, 7:13 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers
Conditions
Cataracts, Retina Surgery, Glaucoma, Any Condition That Requires Ophthalmic Drops
Interventions
Not listed
Lead sponsor
Alexander Eaton
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Fort Myers, Florida
Source: ClinicalTrials.gov public record
Updated Dec 27, 2015 · Synced May 21, 2026, 7:13 PM EDT
Conditions
Glaucoma, Ocular Hypertension
Interventions
bimatoprost 0.01%, travoprost 0.004%, timolol 0.5%, hypromellose 0.3%
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Racine, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 13, 2016 · Synced May 21, 2026, 7:13 PM EDT
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
PG324 Ophthalmic Solution 0.01%, PG324 Ophthalmic Solution 0.02%, Netarsudil (AR-13324) Ophthalmic Solution 0.02%, Latanoprost Ophthalmic Solution 0.005%
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
23
States / cities
Artesia, California • Inglewood, California • Newport Beach, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2019 · Synced May 21, 2026, 7:13 PM EDT
Completed Phase 4 Interventional Results available
Conditions
Intraocular Pressure, Glaucoma, Ocular Hypertension
Interventions
0.01% bimatoprost
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
40 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 18, 2014 · Synced May 21, 2026, 7:13 PM EDT
Conditions
Glaucoma, Ocular Hypertension
Interventions
Latanoprostene bunod
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
20 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 25, 2018 · Synced May 21, 2026, 7:13 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers
Conditions
Intraocular Pressure
Interventions
Increasing of intraocular pressure (IC)
Diagnostic Test
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 90 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced May 21, 2026, 7:13 PM EDT
Conditions
Elevated Intraocular Pressure
Interventions
Latanoprost ophthalmic solution, 0.005%, TC-002 latanoprost ophthalmic solution, 0.005%
Drug
Lead sponsor
TearClear Corp
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
20
States / cities
Garden Grove, California • Glendale, California • Mission Hills, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced May 21, 2026, 7:13 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers
Conditions
Glaucoma, Visual Field Defect
Interventions
Visual Field Perimeter Optimized with Eye Gaze Capture and Artificial Intelligence
Device
Lead sponsor
Sight Intelligence Engineering Corporation
Industry
Eligibility
18 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Alexandria, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 2, 2025 · Synced May 21, 2026, 7:13 PM EDT
Conditions
Glaucoma and Ocular Hypertension
Interventions
DE-117 Ophthalmic Solution, Timolol Maleate Ophthalmic Solution 0.5%
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
12 Months and older
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
47
States / cities
Phoenix, Arizona • Sun City, Arizona • Burbank, California + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced May 21, 2026, 7:13 PM EDT
Conditions
Glaucoma, Ocular Hypertension
Interventions
RKI983A, Latanoprost
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
29
States / cities
Artesia, California • Inglewood, California • La Jolla, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced May 21, 2026, 7:13 PM EDT
Conditions
Ocular Hypertension, Open Angle-glaucoma
Interventions
ONO-9054, Latanoprost
Drug
Lead sponsor
Ono Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 85 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
12
States / cities
Los Angeles, California • Mission Hills, California • Newport Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2016 · Synced May 21, 2026, 7:13 PM EDT
Conditions
Glaucoma, Glaucoma Eye, Glaucoma, Open-Angle
Interventions
Lumega-Z, Dorzolamide Hcl 2% Oph Soln, Placebo
Dietary Supplement · Drug · Other
Lead sponsor
University of the Incarnate Word
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 3, 2022 · Synced May 21, 2026, 7:13 PM EDT
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
PG324 Ophthalmic Solution 0.02%/0.005%, Netarsudil (AR-13324) ophthalmic solution 0.02%, Latanoprost ophthalmic solution 0.005%
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Bedminster, New Jersey
Source: ClinicalTrials.gov public record
Updated May 20, 2019 · Synced May 21, 2026, 7:13 PM EDT
Conditions
Glaucoma, Ocular Hypertension
Interventions
ibuprofen, latanoprost, brimonidine, Ibuprofen, brimonidine, latanoprost, Ibuprofen
Drug
Lead sponsor
Philadelphia Eye Associates
Other
Eligibility
21 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
3
States / cities
Willingboro, New Jersey • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced May 21, 2026, 7:13 PM EDT
Conditions
Glaucoma
Interventions
endoscopic goniotomy
Device
Lead sponsor
Vanderbilt University
Other
Eligibility
1 Week to 3 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2007
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 7, 2013 · Synced May 21, 2026, 7:13 PM EDT
Conditions
Cataract, Glaucoma, Ocular Hypertension
Interventions
Bimatoprost Implant System, SpyGlass IOL, Timolol Maleate Ophthalmic Solution, 0.5%, Commercial IOL
Drug · Device
Lead sponsor
SpyGlass Pharma, Inc.
Industry
Eligibility
22 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced May 21, 2026, 7:13 PM EDT
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
Vehicle of DE-126 Ophthalmic Solution, high dose of DE-126 Ophthalmic Solution, Topical ultra-low dose of DE-126 Ophthalmic Solution, Topical low dose of DE-126 Ophthalmic Solution, Topical medium dose of DE-126 Ophthalmic Solution, Topical high dose of DE-126 Ophthalmic Solution, 0.005% Latanoprost Ophthalmic Solution
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
12
States / cities
Artesia, California • Mission Hills, California • Newport Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced May 21, 2026, 7:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available
Conditions
Hemianopia, Hemianopsia, Peripheral Visual Field Defect, Blindness, Retinitis Pigmentosa, Glaucoma
Interventions
Collision warning device
Device
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 9, 2021 · Synced May 21, 2026, 7:13 PM EDT
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
G2-TR intraocular implant containing travoprost, Sham surgery + active-comparator eye drops
Combination Product · Drug
Lead sponsor
Glaukos Corporation
Industry
Eligibility
18 Years and older
Enrollment
590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Nov 28, 2024 · Synced May 21, 2026, 7:13 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers
Conditions
Primary Open Angle Glaucoma
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
1,540 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2022
U.S. locations
3
States / cities
Birmingham, Alabama • La Jolla, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 5, 2021 · Synced May 21, 2026, 7:13 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available
Conditions
Glaucoma
Interventions
Latanoprost, Dorzolamide, Timolol
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced May 21, 2026, 7:13 PM EDT